Filtering by content type: Blog Post
Fans of “Shark Tank” will remember it as one of the show’s most dramatic bidding wars. Charles Yim, CEO of Breathometer, pitched his smartphone-enabled breathalyzer as a way to “help people make smarter and safer decisions” about drinking and driving. All five sharks went for the...
Ads for Prevagen claimed that the purported memory improvement supplement is “The Name to Remember,” but according to a lawsuit filed by the FTC and the New York Attorney General, it’s a product consumers might be better off forgetting.
“Just like the white winged dove sings a song,” you can count on the BCP Business Blog to celebrate the “Edge of Seventeen” – 2017, of course – with a recap of in-case-you-missed-it developments from 2016. (Sorry, Stevie Nicks. That was a stretch.) In no particular order, here is our...
Is it time for a little heart-to-heart about making health claims for mobile apps? An FTC settlement with California-based Aura Labs challenges misleading representations the company made about its Instant Blood Pressure app. In addition, if you keep your finger on the pulse of FTC...
The FTC applies a consistent approach to evaluating ad claims. Companies must have a reasonable basis for objective representations, including claims that a product can treat specific health conditions. Whether it’s an over-the-counter drug, dietary supplement, or food, the same...
In an eye exam, the bottom line is the toughest to see. But responsible eye care prescribers and contact lens sellers clearly understand another “bottom line”: They comply with the FTC’s Contact Lens Rule.
Filtering by content type: Press Release
The marketers of two app-supported smartphone accessories, marketed to accurately measure consumers’ blood alcohol content (BAC), have agreed to settle Federal Trade Commission charges that they lacked scientific evidence to back up their advertising claims.
The Federal Trade Commission and New York State Attorney General have charged the marketers of the dietary supplement Prevagen with making false and unsubstantiated claims that the product improves memory, provides cognitive benefits, and is “clinically shown” to work.
Following a public comment period, the Federal Trade Commission has approved a final consent order with Mars Petcare U.S. settling charges that the company falsely advertised specific health benefits of its Eukanuba brand dog food.
The Federal Trade Commission has granted summary decision against California Naturel, Inc., for falsely advertising its sunscreen product as “all natural” in violation of Sections 5 and 12 of the FTC Act.
The marketers of a mobile app designed to measure blood pressure have agreed to settle Federal Trade Commission charges that they deceived consumers with claims that their Instant Blood Pressure (IBP) app was as accurate as a traditional blood pressure cuff. In addition, the Commission alleged...
The Federal Trade Commission today announced a new “Enforcement Policy Statement on Marketing Claims for Over-the-Counter (OTC) Homeopathic Drugs.” The policy statement was informed by an FTC workshop held last year to examine how such drugs are marketed to consumers.
At the request of the Federal Trade Commission, a U.S. district court judge issued a summary decision and $30 million judgment against the pitchman behind a product called Pure Green Coffee, who deceived consumers using false weight-loss claims, bogus testimonials, and fake news websites.
Filtering by content type: Case
Filtering by content type: Public Statement
Federal Register Notice: Federal Trade Commission Enforcement Policy Statement on Marketing Claims for Over-the-Counter Homeopathic Drugs
Filtering by content type: Report